研究发现,对食用过敏的口服免疫疗法比对口服免疫疗法更有效、更安全。 Study finds omalizumab more effective and safer than oral immunotherapy for food allergies.

Johns Hopkins儿童中心和NIH的一项新研究发现,用于食品过敏的注射药物Omalizumab优于口服免疫疗法(OIT)。 A new study by Johns Hopkins Children's Center and NIH found that omalizumab, an injectable drug for food allergies, outperforms oral immunotherapy (OIT). 研究显示,在食疗上,36%的人可以忍受多种食物过敏,而在OIT上,这一比例为19%。 The study showed that 36% of those on omalizumab could tolerate multiple food allergens compared to 19% on OIT. Omalizumab也没有产生严重的副作用,而30%以上的OIT参与者经历了不良反应。 Omalizumab also had no severe side effects, while over 30% of OIT participants experienced adverse reactions. 这项研究为临床医生推荐最有效的食品过敏治疗方法提供了重要信息。 This study provides crucial information for clinicians to recommend the most effective treatment for food allergies.